Companies
WHOOP
wrist-worn HRV and recovery-tracking band, adopted by elite sport organizations for recovery-as-tactics programs; cited in a 2025 peer-reviewed study on heart-rate recurrence as a biosignature of esports team victory and in ongoing research on predicting "tilt" (emotional dysregulation) in competitive gaming.
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| cross-sector-intersections | ✓ | ✓ | ✓ |
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaedpbftcreach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $575 million Series G round in March 2026, bringing total funding to over $1 billion | sacra.com · bloomberg.com |
| Production site | WHOOP-owned facility in Mexico and a manufacturing partner in China | community.whoop.com |
| Certification | FDA 510(k) clearance (K243236) for single lead ECG on WHOOP MG device (April 2025) | weguide.health |
| Regulatory approval | Single lead ECG for atrial fibrillation is FDA cleared; Blood Pressure Insights feature is considered wellness data under enforcement discretion, not cleared | weguide.health |
| Revenue | Estimated $1.1 billion in annualized bookings in 2025 medium confidence | sacra.com |
Independent sources: bloomberg.com · sacra.com · weguide.health
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biometric e-sports performance systems | cross-sector-intersections | Medium | → |
| Sports bioeconomy | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.